# Vall d'Hebron Hospital Universitari

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/vall-d-hebron-hospital-universitari/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 53.1 |
| Citations | 2,929,695 |
| City | Barcelona |
| Country | ES |
| Description | Vall d'Hebron Hospital Universitari is a research organisation in Barcelona, ES. OpenAlex records 37,437 works and 2,929,695 citations for it. 10,268 researchers list it as their most recent affiliation. |
| Homepage | https://www.vallhebron.com |
| OpenAlex ID | https://openalex.org/I4210127641 |
| Region | Catalonia |
| Researchers | 10,268 |
| ROR ID | https://ror.org/03ba28x55 |
| Type | healthcare |
| Works | 37,437 |

## University papers

Showing 12 of 24.

- [Vascular dementia](https://scholariq.org/papers/vascular-dementia/)
- [Inborn errors of type I IFN immunity in patients with life-threatening COVID-19](https://scholariq.org/papers/inborn-errors-of-type-i-ifn-immunity-in-patients-with-life-threatening-covid-19/)
- [Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions](https://scholariq.org/papers/banff-07-classification-of-renal-allograft-pathology-updates-and-future/)
- [Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection](https://scholariq.org/papers/antibody-mediated-rejection-criteria-an-addition-to-the-banff-97-classification/)
- [Esophageal motility disorders on high‐resolution manometry: Chicago classification version 4.0<sup>©</sup>](https://scholariq.org/papers/esophageal-motility-disorders-on-high-resolution-manometry-chicago/)
- [The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials](https://scholariq.org/papers/the-banff-2017-kidney-meeting-report-revised-diagnostic-criteria-for-chronic/)
- [The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection](https://scholariq.org/papers/the-banff-2019-kidney-meeting-report-i-updates-on-and-clarification-of-criteria/)
- [Clinical picture and treatment of 2212 patients with common variable immunodeficiency](https://scholariq.org/papers/clinical-picture-and-treatment-of-2212-patients-with-common-variable/)
- [The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology](https://scholariq.org/papers/the-banff-2015-kidney-meeting-report-current-challenges-in-rejection/)
- [EFNS guidelines on neuropathic pain assessment: revised 2009](https://scholariq.org/papers/efns-guidelines-on-neuropathic-pain-assessment-revised-2009/)
- [Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-brafv600e-mutated-biliary-tract/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.